持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

中低位直肠癌侧方淋巴结阳性的危险因素分析

目的探讨影响中低位直肠癌侧方淋巴结阳性的危险因素。 方法回顾性分析2019年1月1日至2020年12月30日两家医院102例中低位直肠癌行腹腔镜根治性切除并进行侧方淋巴结清扫术患者的临床资料,根据侧方淋巴结转移情况将其分为阳性组（n=21例）和阴性组（n=81例）。临床数据采用SPSS 22.0软件进行统计学分析,计数资料以［n（%）］表示,采用χ²或Fisher精确检验;侧方淋巴结阳性的危险因素采用Logistic多因素分析。以P<0.05为差异有统计学意义。 结果102例中低位直肠癌患者侧方淋巴结清扫总数为1347枚,其中阳性淋巴结占比为8.1%;单因素分析结果显示,患者年龄、肿瘤直径、分化程度、肿瘤类型、T分期及浸润肠壁程度与侧方淋巴结阳性的发生均有明显相关性（P<0.05）;Logistic回归分析显示,低分化、浸润型、T_3-4期及浸润肠壁浆膜外肿瘤是中低位直肠癌侧方淋巴结阳性的独立危险因素（P<0.05）。 结论中低位直肠癌患者肿瘤组织低分化、浸润型癌、肿瘤分期T_3-4及浸润肠壁浆膜外可作为判断侧方淋巴结转移的独立危险因素,建议对存在这些危险因素的患者行侧方淋巴结清扫术。     

腹腔镜联合胆道镜治疗胆总管结石的临床分析

目的：探讨腹腔镜联合胆道镜治疗胆总管结石的临床疗效。方法：选择胆总管结石患者50例,行腹腔镜下胆总管切开胆道镜取石放T管引流术。观察患者术中、术后情况,评价手术治疗效果。结果：所有手术均获得成功,平均手术时间为（85±20）min,平均术中出血量为（20±5）ml,平均术后排气时间为（1.1±0.3）d,平均术后住院时间为（6±1）d,所有患者均未出现严重并发症。结论：腹腔镜联合胆道镜治疗胆总管结石能减少创伤,促进恢复,是治疗胆总管结石较为安全的微创手术方式。     

PG－SGA评分对结肠癌患者根治术后并发症的预测价值

目的探究PG－SGA评分对结肠癌患者根治术后并发症的预测价值。 方法回顾分析2014年6月至2018年12月接受手术治疗的200例结肠癌患者临床资料,采用PG－SGA评分对所有患者进行术前营养状况评价,按照有无营养风险分为营养正常组(PG－SGA评分≥4,112例)和营养不良组(PG－SGA评分<4,88例),采用SPSS19.0软件对数据进行统计学分析。围手术期各项指标等计量资料行( ±s)表示,组间行独立t检验,术后并发症行χ²检验或Fisher确切概率法,P<0.05时差异具有统计学意义。 结果两组患者在性别、年龄、病变部位、ASA评分、分化程度、TNM分期、肿瘤大小和病理类型方面差异无统计学意义(P>0.05);营养正常组患者住院时间和住院费用明显少于于营养不良组(P<0.05);术后并发症发生率为8.0%明显低于营养不良组32.9%,差异具有统计学意义(χ²＝6.98, P<0.05)。 结论PG－SGA评分<4的结肠癌患者术后并发症的发生率较高,值得临床重视。     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

谷氨酰胺在胃肠道术后患者全胃肠外营养中的疗效评价

目的:探讨在胃肠术后予加入谷氨酰胺的TPN的疗效。方法:32例胃肠道手术患者随即均分为对照组和Gln组,对两组病人胃肠功能恢复情况、术前术后蛋白质合成、氮平衡及等情况进行比较。结果:Gln组患者的并发症发生率及住院时间均较对照组低,并有显著性差异(p<0.05);同时,肠功能恢复时间Gln组(58.7±8.7)h短于对照组(60.3±6.7)h,但两组间差异无统计学意义;两组术后12d血清白蛋白、前白蛋白均有回升,但对照TPN组均明显低于Gln组,差异有统计学意义(P<0.05);术后第8d Gln组氮平衡的改善明显优对照组(P<0.05)。结论:加用谷氨酰胺的TPN的疗效是有利于改善胃肠道术后患者营养状况和促进胃肠功能的恢复。     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.